CARD9 and inflammatory bowel disease: Furthermore, 33 311 clinical cases with the protective Δ11 splice variant were less likely to develop IBD regardless of the presence of the predisposing S12N mutation, which further verified an important biological role for the C‐terminus of CARD9.